Based in Illinois and employing 80 people, Microbiome Labs offers proprietary probiotic and microbiome solutions for the gastrointestinal, immune, metabolic and cognitive health sectors.
“Within a few years, Microbiome Labs has built a solid market position and become a key opinion leader on the microbiome in the consumer health industry,” said Novozymes CEO Ester Baiget.
Under the terms of the deal, Novozymes will make a cash payment of about 780 million Danish kroner (about $125 million). The agreement includes an earn-out model under which Novozymes could pay up to 100% of the upfront sum, contingent on “very ambitious” sales targets being achieved in 2022. Microbiome Labs posted revenues of approximately 250 million Danish kroner – or $40 million – in 2020.
The takeover of Microbiome Labs is the second this year for Novozymes in the probiotic space. In June, the Bagsværd-headquartered company purchased Ireland’s PrecisionBiotics Group, a specialist in probiotics for gut health, for 600 million Danish kroner, about €80 million.
Author: Elaine Burridge, Freelance Journalist
